CORDIS
EU research results

CORDIS

English EN
Open Research Biopharmaceutical Internships Support

Open Research Biopharmaceutical Internships Support

Objective

The current process of drug development is lengthy and inefficient. Only 1 out of approximately 10,000 drug molecules enters the market. Therefore more effective medicines, demanded by society, cannot be provided by pharmaceutical industry. To fill this gap, Open Research Biopharmaceutical Internships Support (ORBIS) proposes that the high attrition rate of new drug candidates might be reduced by over 20% by improving early stage R&D productivity. The overarching objective of ORBIS is therefore to form an international and inter-sectoral academic and industrial network. The action is aimed at improving the preclinical pathway of medicine development concentrating on processes and technologies. The goal is to integrate multidisciplinary research by involving academia and industry from EU (Poland, Ireland, Finland, Germany and Czech Republic), EU associated country (Ukraine) and US to address the poor drug bioavailability as 70% of actives have solubility and/or membrane permeability problems. The action is addressed at selected molecules of class II and IV of Biopharmaceutics Classification System, to improve their pharmaceutical potential. The complementary consortium comprises experts in computations, physical chemistry, material science, nanotechnology, pharmacy, pharmacology and bioanalysis. The secondments will create a stimulating environment for early stage researchers to advance their individual career and soft skills. EU scientists will amalgamate their expertise in drug synthesis and dissolution, oral formulations, and bioanalytical methods with the knowledge on dermal research provided by the US partner. ORBIS will consolidate the existing links, promote long-term cooperation and exchange of knowledge between beneficiaries and partners. ORBIS will also enhance dissemination of new research outcomes and raise the awareness among the general public of the importance of drug delivery research that makes new drugs more accessible and affordable for society.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU

Address

Ul. Fredry 10
61-701 Poznan

Poland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 684 000

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

JOINT STOCK COMPANY FARMAK

Ukraine

EU Contribution

€ 315 000

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 112 500

INSTYTUT FARMACEUTYCZNY

Poland

EU Contribution

€ 274 500

PHYSIOLUTION GMBH

Germany

EU Contribution

€ 45 000

APPLIED PROCESS COMPANY LIMITED

Ireland

EU Contribution

€ 27 000

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 171 000

ZENTIVA, K.S.

Czechia

EU Contribution

€ 270 000

POLITECHNIKA POZNANSKA

Poland

EU Contribution

€ 369 000

Partners (1)

Sort alphabetically

Expand all

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Project information

Grant agreement ID: 778051

Status

Ongoing project

  • Start date

    1 March 2018

  • End date

    28 February 2022

Funded under:

H2020-EU.1.3.3.

  • Overall budget:

    € 2 268 000

  • EU contribution

    € 2 268 000

Coordinated by:

UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU

Poland